Drug Search Results
More Filters [+]


Alternative Names: asenapine, saphris, secuado, asenapinmaleat, sycrest
Latest Update: 2024-02-09
Latest Update Note: Clinical Trial Update

Product Description

Asenapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Asenapine is used alone or in combination with other medications to treat or prevent episodes of mania (frenzied, abnormally excited mood) or mixed mania (frenzied, abnormally excited mood and symptoms of depression) in adults and children 10 years of age and older with bipolar I disorder (manic depressive disorder; a disease that causes episodes of mania, episodes of depression and other abnormal moods). Asenapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a610015.html)

Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Sublingual

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States

Approved Indications: Schizophrenia | Bipolar Disorder | Schizophrenia

Known Adverse Events: Weight Gain | Bipolar Disorder | Dizziness | Schizophrenia

Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Asenapine

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Schizophrenia



Trial Status


Primary Completion Date

Probability of Success



Not yet recruiting



Recent News Events